Multimodal platform for assessing drug distribution and response in clinical trials

Response to targeted therapy varies between patients for largely unknown reasons. Here, we developed and applied an integrative platform using mass spectrometry imaging (MSI), phosphoproteomics, and multiplexed tissue imaging for mapping drug distribution, target engagement, and adaptive response to gain insights into heterogeneous response to therapy.Patient-derived xenograft (PDX) lines of glioblastoma were treated with adavosertib, a Wee1...